Journals / Acta Medica / 2019 / Cilt: 50 - Sayı: 2

Role of Tumor Necrosis Factor Alpha Promoter Polymorphisms in Interferon Related Side Effects in Chronic Hepatitis B Patients Under Interferon Alpha 2b Treatment

Pages
32–38
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: TNF alpha promoter polymorphisms do not contribute to oc-currence of IFN alpha treatment related side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Interferon alpha therapy is associated with series of adverse ef-fects leading premature discontinuation of treatment.
📊
Key Findings & Data:Here we aimed to de-termine the effects of Tumor necrosis alpha promoter polymorphisms on in-terferon related side effects during interferon alpha 2b treatment in chron-ic hepatitis B patients.Material and Methods: This observational study enrolled 50 chronic hepati-tis B patients, who were treated with interferon alpha 2b 10 tiw plus lamivu-dine 100mg/day at Selçuk University Meram Medical Faculty Department of Infectious Diseases and Clinical Bacteriology between 2006-2007.
💡
Conclusion & Impact:Conclusion: TNF alpha promoter polymorphisms do not contribute to oc-currence of IFN alpha treatment related side effects.
🔬Design:Survey & Empirical Study
📍Scope:2006-2007 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Interferon alpha therapy is associated with series of adverse ef-fects leading premature discontinuation of treatment. Here we aimed to de-termine the effects of Tumor necrosis alpha promoter polymorphisms on in-terferon related side effects during interferon alpha 2b treatment in chron-ic hepatitis B patients.Material and Methods: This observational study enrolled 50 chronic hepati-tis B patients, who were treated with interferon alpha 2b 10 tiw plus lamivu-dine 100mg/day at Selçuk University Meram Medical Faculty Department of Infectious Diseases and Clinical Bacteriology between 2006-2007. Patients were followed-up with complete blood count, transaminases and amylase monthly at out patient clinics of our department. All patients were asked to fill a questionnaire to evaluate the interferon related side effects at every vis-it. Tumor necrosis factor alpha -238 and -308 polymorphisms were investi-gated with PCR-Restriction fragment length polymorphisms.Results: Arthralgia was present in 93.8% of patients. Exhaustion, loss of ap-petite, mount dryness and fever are the leading complaints of the patients. Median complaint scores were 9, 9.5, 11 and 5 at 4th, 12th, 24th and 48th week visits, respectively. Thrombocytopenia and leucopenia were detected in 8 (16%) and 5 (10%) patients, respectively. One-third of the patients report-ed depressive mood however, depression was diagnosed in 5 (10%) patients. TNF alpha promoter 238GG and 308GG allele was present in 42/50 and 43/50 patients, respectively. No association was found between TNF pro-moter allele and certain patient-reported side effect, complaint score, hema-tological and psychological adverse effects. Conclusion: TNF alpha promoter polymorphisms do not contribute to oc-currence of IFN alpha treatment related side effects.

🔖

Cite This Article

İNKAYA, A. Ç., ARIBAŞ, E. T., KANDEMİR, B., ACAR, H., BİTİRGEN, M. (2019). Role of Tumor Necrosis Factor Alpha Promoter Polymorphisms in Interferon Related Side Effects in Chronic Hepatitis B Patients Under Interferon Alpha 2b Treatment. Acta Medica, Cilt: 50 - Sayı: 2, 32–38. https://ajindex.com/articles/143132

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Lavanchy D. Hepatitis B virus epidemiology, disease bur-den, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. World Health Organization. Hepatitis B Fact Sheet No. 204, Revised October 2000.
  2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hep-atitis B: 2000–summary of a workshop. Gastroenterol 20 01; 120: 1828 -1853. Özkan, H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepato-Gastroenterol 2018; 8: 73-76.[5]Thomas H, Foster G, Platis D. Mechanisms of action of in-terferon and nucleoside analogues. J Hepatol 2003; 39: S93–S98. Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of in-terferon-a therapy. Pharm World Sci 2005; 27: 423–431. D’Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150–4. Hadziyannis SJ, and Papatheodoridis GV. Hepatitis B e Antigen–Negative Chronic Hepatitis B: Natural History and Treatment. Semin Liver Dis 2006; 26: 130–141.
  3. Chuaypen N, Posuwan, N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBeAg kinetics in pa-tients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy. Clin Microbiol Inf 2018; 24(3): 306-e7. Bourlière M, Rabiega P, Ganne-Carrie N, et al. Effect on HBs antigen clearance of addition of pegylated interfer-on alfa-2a to nucleos (t) ide analogue therapy versus nu-cleos (t) ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained un-detectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2 017; 2(3): 17 7-18 8. Azhari H, Swain MG, Role of Peripheral Inflammation in Hepatic Encephalopathy, Clin Exp Hepatol 2018; 8(3):281-285.
  4. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors Cellular signalling 2012; 24(6): 1297-13 05. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interfer-on combination therapy in anti-HBe positive chronic hep-atitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799–804.
  5. Yuki N, Nagaoka T, Nukui K, et al. Adding interferon to lamivudine enhances the early virologic response and re-version of the precore mutation in difficult-to-treat HBV infection J Gastroenterol 2008; 43(6): 457-463.
  6. Dinarello CA, Bernheim HA, Duff GW, et al. Mechanisms of fever induced by recombinant interferon. J Clin Invest 1984; 74(3): 906–13.
  7. Cameron DA, Cornbleet MC, Mackie RM, e